Reversal of liver cirrhosis in autoimmune hepatitis

Hepato-Gastroenterology

Volumn 58, Issue 112, 2011, Pages 2115-2117

  Shah, Anish M ^a   Malhotra, Ashish ^b   Kothari, Shivangi ^b   Baddoura, Walid ^b   DePasquale, Joseph ^b   Spira, Robert ^b  

^a Department of Internal Medicine   (United States)

^b SETON HALL UNIVERSITY   (United States)

Author keywords

Autoimmune hepatitis; Cirrhosis; Reversal of cirrhosis

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; MERCAPTOPURINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; AUTOIMMUNE HEPATITIS; BILIRUBIN BLOOD LEVEL; CASE REPORT; DRUG DOSE REDUCTION; FEMALE; FOLLOW UP; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTERNATIONAL NORMALIZED RATIO; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FUNCTION TEST; MALE; PRIORITY JOURNAL; PROTHROMBIN TIME; SMOKING;

ADULT; FEMALE; HEPATITIS, AUTOIMMUNE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER CIRRHOSIS; MALE; MIDDLE AGED;

EID: 84857665724     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: 10.5754/hge09768     Document Type: Article

References (17)

1. Crawford JM: The liver and the biliary tract. In: Cotran RS, Robbins SL, Kumar V, Schoen FJ, eds. Pathologic Basis of Disease. 5th ed. Philadelphia: WB Saunders; 1994:831-96.
2. Hall PD: Alcoholic liver disease. In: MacSween RN, Anthony PP, Scheuer PJ, eds. Pathology of the Liver. 2d ed. New York: Churchill Livingstone; 1987:291.
3. Schvarcz R, Glaumann H, Weiland O: Survival and histological resolution of fibrosis in patients with autoimmune chronic active hepatitis. J Hepatol 1993; 18:15-23. (Pubitemid 23166347)
4. Dufour JF, DeLellis R, Kaplan MM: Reversibility of hepatic fibrosis in autoimmune hepatitis. Ann Intern Med 1997; 127:981-985. (Pubitemid 27516609)
5. Cotler SJ, Jakate S, Jensen DM: Resolution of cirrhosis in autoimmune hepatitis with corticosteroid therapy. J Clin Gastroenterol 2001; 32:428-430. (Pubitemid 32378277)
6. Czaja AJ, Carpenter HA: Progressive fibrosis during corticosteroid therapy of autoimmune hepatitis. Hepatology 2004; 39:1631.
7. Friedman SL: The cellular basis of hepatic fibrosis. Mechanisms and treatment strategies. N Engl J Med 1993; 328:1828-1835.
8. Bonis PAL, Friedman SL, Kaplan MM: Is liver fibrosis reversible (editorial). N Engl J Med 2001; 344:452-454.
9. Arthur MJP: Reversibility of liver fibrosis and cirrhosis following treatment for hepatitis C (editorial). Gastroenterology 2002; 122:1525-1528.
10. Friedman SL: Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J Biol Chem 2000; 275:2247-2250.
11. Feld JJ, Dinh H, Arenovich T, et al.: Autoimmune hepatitis: effect of symptoms and cirrhosis on natural history and outcome. Hepatology 2005; 42:53.
12. Kogan J, Safadi R, Ashur Y, et al.: Prognosis of symptomatic versus asymptomatic autoimmune hepatitis: a study of 68 patients. J Clin Gastroenterol 2002; 35:75.
13. Czaja AJ, Carpernter HA: Decreased fibrosis during corticosteroid therapy of autoimmune hepatitis. J Hepatol 2004; 40:646-652. (Pubitemid 38367787)
14. Ustundag G, Kuloglu Z, Kirsaclioglu CT, et al.: Complete regression of cirrhosis after immunosuppressive treatment in autoimmune hepatitis. Pediatr Int 2008; 50:711-713.
15. Mohamadnejad M, Malekzadeh R, Nasseri-Moghaddam S, et al.: Impact of immunosuppressive treatment on liver fibrosis in autoimmune hepatitis. Dig Dis Sci 2005; 50:547-551. (Pubitemid 40543746)
16. Seo S, Toutounjian R, Conrad A, et al.: Favorable outcomes of autoimmune hepatitis in a community clinic setting Hepatology 2008; 23:1410-1414.
17. Czaja AJ: Genetic factors affecting the occurrence, clinical phenotype, and outcome of autoimmune hepatitis. Clin Gastroenterol Hepatol 2008; 6:379-388.